<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4838">
  <stage>Registered</stage>
  <submitdate>22/12/2014</submitdate>
  <approvaldate>22/12/2014</approvaldate>
  <nctid>NCT02343406</nctid>
  <trial_identification>
    <studytitle>Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas</studytitle>
    <scientifictitle>Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase II Study of the EORTC Brain Tumor Group (EORTC Protocol 1410-BTG) Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas</scientifictitle>
    <utrn />
    <trialacronym>INTELLANCE 2</trialacronym>
    <secondaryid>2014-004438-24</secondaryid>
    <secondaryid>M14-483</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Glioblastoma Multiforme</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Brain</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ABT-414
Treatment: drugs - Lomustine
Treatment: drugs - Temozolomide

Experimental: Arm 1 - ABT-414 administered via intravenous infusion every two weeks in combination with Temozolomide

Experimental: Arm 2 - ABT-414 administered every two weeks as monotherapy

Active Comparator: Arm 3A - Lomustine: For patients relapsing during TMZ treatment, or within 16 weeks after first day of last TMZ cycle: Lomustine will be administered on day 1 of every 42 day cycle.

Active Comparator: Arm 3B - Temozolomide re-challenge: For patients that relapse 16 weeks or more after the first day of last dose of TMZ cycle: TMZ will be administered on day 1-5 of every 28 day cycle

Experimental: Arm 4 Pediatric sub-study - ABT-414 at a dose of 1.0 mg/kg for participants who are 6 to 17 years old (at the date of first ABT-414 dose), or 1.3 mg/kg for participants who are 0 to 5 years old administered via intravenous infusion every other week. Prophylactic steroid eye drops (temozolomide) will be administered as described for the adult participants. Investigator discretion to use ABT-414 as monotherapy or in combination with temozolomide. The use of TMZ in combination with ABT-414 for a pediatric patient must be reviewed by the EORTC/AbbVie medical monitor prior to the initiation of therapy.


Treatment: drugs: ABT-414
ABT-414 will be administered by intravenous infusion over approximately 30-40 minutes.

Treatment: drugs: Lomustine
Lomustine will be administered orally.

Treatment: drugs: Temozolomide
Temozolomide (TMZ) will be administered orally.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Adult study: Overall Survival (OS) - Overall Survival (OS) is defined as number of days from the date of randomization to the date of death for all dosed participants.</outcome>
      <timepoint>Measured from the date of randomization up to the date of participant's death. Participants who complete treatment will be assessed every 12 weeks, up to 28 months.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Adult study: Progression Free Survival (PFS) - Progression Free Survival per RANO criteria is the length of time during and after the treatment of a disease, that the participant lives with the disease but does not get worse.</outcome>
      <timepoint>PFS will be measured every 8 weeks from date of randomization until the date of first objective progression or participant's death, whichever occurs first, up to 2 years. This will be assessed at interim analysis, when 45 PFS events are observed.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pediatric study: Safety including toxicities according to CTCAE criteria - The severity of each adverse event is rated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE Version 4.0)</outcome>
      <timepoint>From participants first visit until 35 days after the participant's last dose of study drug</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pediatric study: Maximum observed serum concentration (Cmax) for ABT-414 - Cmax is the peak concentration that a drug achieves in a specified compartment after the drug has been administrated and before administration of a second dose.</outcome>
      <timepoint>Samples collected at various time points from Cycle 1 Day 1 up to 35 days after the participant's last dose of study drug</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pediatric study: Half-life (t1/2) observed for ABT-414 - Half-life is the calculated time it takes for half of the drug to leave the body.</outcome>
      <timepoint>Samples collected at various time points from Cycle 1 Day 1 up to 35 days after the participant's last dose of study drug.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pediatric study: Area Under the Concentration-time Curve (AUC) observed for ABT-414 - AUC is a measure of how long and how much drug is present in the body after dosing. AUC in pediatric population will be compared following treatment, to check that this is comparable to adults, and the dosing levels are appropriate for a pediatric population.</outcome>
      <timepoint>Samples collected at various time points from Cycle 1 Day 1 up to 35 days after the participant's last dose of study drug.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pediatric study: Maximum observed plasma concentration (Cmax) for Cys-mcMMAF (toxin, identified as a metabolite of ABT-414) - Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose.</outcome>
      <timepoint>Samples collected Cycle 1 Days 1, 2, 3, 5, 8</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pediatric study: t1/2 for Cys-mcMMAF (toxin, identified as a metabolite of ABT-414) - Half-life is the calculated time it takes for half of the drug or drug metabolite to leave the body.</outcome>
      <timepoint>Samples collected Cycle 1 Days 1, 2, 3, 5, 8</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pediatric study: AUC for Cys-mcMMAF (toxin, identified as a metabolite of ABT-414) - AUC is a measure of how long and how much drug or drug metabolite is present in the body after dosing. AUC in pediatric population will be compared following treatment, to check that this is comparable to adults, and the dosing levels are appropriate for a pediatric population.</outcome>
      <timepoint>Samples collected Cycle 1 Days 1, 2, 3, 5, 8</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Adult study: Progression Free Survival (PFS) - Progression Free Survival per RANO criteria is the length of time during and after the treatment of a disease, that the participant lives with the disease but does not get worse.</outcome>
      <timepoint>Progression Free Survival will be measured every 8 weeks from date of randomization until the date of first objective progression or date of participant's death, whichever occurs first, assessed up to 28 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adult study: Overall Response Rate (ORR) - Overall Response Rate will look at those complete responders and partial responders</outcome>
      <timepoint>The overall response rate will be evaluated every 8 weeks at each assessment of disease according to RANO criteria, up to 28 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adult study: Overall Survival in the subgroup with Epithelial Growth Factor Receptor (EGFRvIII) mutation - Overall Survival (OS) is defined as number of days from the date of randomization to the date of death for all randomized participants that have EGFR vIII mutation.</outcome>
      <timepoint>Measured from date of randomization until death, or lost to follow up, assessed up to 28 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pediatric study: Objective response rate, best response rate and duration of response based on RANO criteria - Objective response includes best overall responses (complete response and partial response)</outcome>
      <timepoint>Evaluated every 8 weeks (+/- 7 days) at each assessment of disease according to RANO criteria, until progression or withdrawal up to approximately 52 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pediatric study: Overall survival, Time to progression and Time to progression-free survival - Overall survival is defined as number of days from the date of enrollment to the date of death for all dosed participation. Progression Free Survival per RANO criteria is the length of time during and after the treatment of a disease, that the participant lives with the disease but does not progress.</outcome>
      <timepoint>Time to progression and time to progression-free survival will be measured every 8 weeks (+/- 7 days) from date of enrollment until the date of first objective progression or participant's death, whichever occurs first, upto approximately 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pediatric study: Changes in neurological status and function (including PedsQL cancer module) - The Pediatric Quality of Life Inventory (PedsQL) is a modular instrument designed to measure health-related quality of life (HRQOL) in children and adolescents ages 2-18 years. Neurological status and functioning will be assessed also at physical examination during the study</outcome>
      <timepoint>Neurological status and functioning is assessed at baseline, day 1 and 15 of each cycle, every 6 months for 5 years thereafter and then annually PedsQL evaluated at baseline, week 16 on treatment and at 6 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adult participants (greater than or equal to 18 years old):

          -  Histologically confirmed de novo (primary) Glioblastoma Multiforme with unequivocal
             tumor progression or recurrence.

          -  In case of testing at the time of first progression: either at least 3 months after
             the end of radiotherapy or have tumor progression that is clearly outside the
             radiation field or have tumor progression unequivocally proven by surgery/biopsy

          -  Absence of any psychological, familial, sociological or geographical factors
             potentially hampering compliance with the study protocol and follow-up schedule; such
             conditions should be assessed with the patient before registration in the trial.

          -  Availability of adequate biological material (formalin-fixed paraffin embedded [FFPE]
             tumor) for central testing of Epithelial Growth Factor Receptor (EGFR) amplification

          -  Presence of EGFR amplification confirmed by central assessment; participants with
             undetermined EGFR status are excluded

          -  World Health Organization (WHO) Performance status 0 - 2

          -  No more than one line of chemotherapy (concurrent and adjuvant Temozolomide based
             chemotherapy including in combination with another investigational agent is considered
             one line of chemotherapy). Chemotherapy must have been completed at least 4 weeks
             prior to randomization.

          -  Post surgery MRI within 48 hours following surgery, however an MRI scan has to be done
             within 2 weeks prior to randomization.

          -  Surgery completed at least 2 weeks before randomization and patients should have fully
             recovered as assessed by investigators.

        Pediatric sub-study participants (less than 18 years old):

          -  The study will only include patients under 3 years of age when results of a juvenile
             repeated mouse toxicity study become available and are favorable to support use in
             patients aged under 3 years.

          -  Histologically proven high grade glioma (HGG: WHO grade III glioma [e.g anaplastic
             astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma], grade IV
             glioma [e.g glioblastoma, gliosarcoma] or diffuse intrinsic pontine glioma [DIPG]).

          -  Must either have recurrent/progressive tumor or, if newly diagnosed, have completed
             any planned radiation therapy at least 4 weeks prior to first dose of ABT-414.

          -  The tumor tissue must have been determined to have EGFR amplification, (by local or
             other testing service).

          -  availability of adequate biological material for retrospective confirmatory central
             testing of EGFR amplification

          -  Participant has sufficiently recovered from previous therapy. The investigator
             believes that benefit of treating the pediatric subject with ABT-414 outweighs the
             expected risks and that this treatment is in the best interests of the pediatric
             subject.</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>99</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Adult population (greater than or equal to 18 years old):

          -  Prior treatment with nitrosoureas

          -  Prior treatment with bevacizumab

          -  Previous exposure to Epithelial Growth Factor Receptor (EGFR) targeted agents,
             including EGFRvIII targeting agents

          -  Prior discontinuation of temozolomide chemotherapy for toxicity reasons

          -  Prior Radiation Therapy (RT) with a dose over 65 Gy, stereotactic radiosurgery or
             brachytherapy unless the recurrence is histologically proven

          -  Previous other malignancies, except for any previous malignancy which was treated with
             curative intent more than 5 years prior to randomization, and except for adequately
             controlled limited basal cell carcinoma of the skin, squamous carcinoma of the skin or
             carcinoma in situ of the cervix

          -  Women of childbearing potential must have a negative serum or urine pregnancy test
             (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to
             randomization.

          -  No history of wheat allergies and Coeliac disease.

          -  No EIAED, patients who require anti-convulsant therapy must be taking non-enzyme
             inducing antiepileptic drugs (non-EIAED). Patients previously on EIAED must be fully
             switched to non-EIAED at least 2 weeks prior to randomization.

        Pediatric sub-study (less than 18 years old):

          -  (For recurrent disease) No prior RT with a dose over 65Gy to the brain, stereotactic
             radiosurgery or brachytherapy unless the recurrence is histologically proven

          -  No current or recent (within 4 weeks or 5 half-lives (whichever is shorter) before
             enrollment) treatment with another investigational drug

          -  Female participants of childbearing potential must have a negative serum or urine
             pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72
             hours prior to randomization.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>11/02/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>260</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>11/06/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Adelaide Hospital /ID# 135208 - Adelaide</hospital>
    <hospital>Barwon Health, University Hospital of Geelong /ID# 134493 - Geelong</hospital>
    <hospital>Royal Brisbane and Women's Hospital /ID# 147091 - Herston</hospital>
    <hospital>Royal Hobart Hospital /ID# 135209 - Hobart</hospital>
    <hospital>Royal Children's Hospital /ID# 157624 - Parkville</hospital>
    <hospital>Port Macquarie Base Hospital /ID# 134569 - Port Macquarie</hospital>
    <hospital>Sydney Children's Hospital /ID# 153533 - Randwick</hospital>
    <hospital>Royal North Shore Hospital /ID# 147092 - St. Leonards</hospital>
    <hospital>Calvary Mater Newcastle /ID# 134570 - Waratah</hospital>
    <hospital>Southern Medical Day Care Center /ID# 134495 - Wollongong</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>7000 - Hobart</postcode>
    <postcode>3052 - Parkville</postcode>
    <postcode>2444 - Port Macquarie</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>2065 - St. Leonards</postcode>
    <postcode>2298 - Waratah</postcode>
    <postcode>2500 - Wollongong</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Graz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Linz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>St. Poelten</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerp</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruges</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Charleroi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Ghent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Montreal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Hradec Kralove</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Ostrava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Prague 5</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Turku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Angers cedex 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bobigny</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bron</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon, Cedex 8</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris, Cedex 13</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Herbalin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich, Bayern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Tuebingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Pecs</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Cork</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bolzano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Padova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seongnam-si</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Monterrey, N.L.</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>The Hague</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Pamplona (Navarra)-Espana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Lausanne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zurich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taoyuan County</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Edgbaston</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Hull</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>European Organisation for Research and Treatment of Cancer - EORTC</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is to evaluate the efficacy and safety of ABT-414 alone or with temozolomide
      versus temozolomide or lomustine alone in participants with recurrent glioblastoma
      multiforme.

      The study includes a Pediatric sub-study to evaluate safety, tolerability and
      pharmacokinetics of ABT-414 in a pediatric population.

      Adult enrollment has been completed and the study is now only recruiting for pediatric
      participants.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02343406</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jim Looman, MD</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>AbbVie_Call Center</name>
      <address />
      <phone>847-283-8955</phone>
      <fax />
      <email>abbvieclinicaltrials@abbvie.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>